A deep dive covering the ANDA pathway, EU MAA procedures, bioequivalence science, Paragraph IV litigation strategy, patent cliff analysis, evergreening […]

The $236 Billion Race Most Procurement Teams Are Losing Between 2025 and 2030, more than $236 billion in branded pharmaceutical

I. Market Context: Why the CDMO Sector Is Repricing The global pharmaceutical CDMO market hit approximately $181.93 billion in 2025,

1. The Cliff Everyone Sees Coming — and Still Falls Off Every branded pharmaceutical product carries a date of death.

An investigative analysis of patent thickets, design-around strategies, and competitive intelligence for pharmaceutical generics manufacturers The Wall Every Generic Manufacturer

A country-by-country guide for pharmaceutical executives, generic manufacturers, and IP professionals operating across 54 markets The Patent Map Nobody Prints

How to conduct a freedom-to-operate analysis that holds up in court, survives investor due diligence, and actually protects your pipeline

An Investigative Analysis of Pharmaceutical and Biotech Valuation Frameworks Why Most Biotech Valuations Get It Wrong Every quarter, analysts revise

What You Actually Need to Know About the Dual Shield Most people conflate drug patents with drug exclusivity. They are